

Elena Lorente

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3471171/publications.pdf>

Version: 2024-02-01

32
papers

298
citations

949033

11
h-index

1051228

16
g-index

32
all docs

32
docs citations

32
times ranked

501
citing authors

#	ARTICLE	IF	CITATIONS
1	Abundance, Betweenness Centrality, Hydrophobicity, and Isoelectric Points Are Relevant Factors in the Processing of Parental Proteins of the HLA Class II Ligandome. <i>Journal of Proteome Research</i> , 2022, 21, 164-171.	1.8	0
2	Acid Stripping after Infection Improves the Detection of Viral HLA Class I Natural Ligands Identified by Mass Spectrometry. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10503.	1.8	2
3	Mitoxantrone Shows In Vitro, but Not In Vivo Antiviral Activity against Human Respiratory Syncytial Virus. <i>Biomedicines</i> , 2021, 9, 1176.	1.4	1
4	Functional Characterization of a Dual Enhancer/Promoter Regulatory Element Leading Human CD69 Expression. <i>Frontiers in Genetics</i> , 2020, 11, 552949.	1.1	1
5	The HLA-DP peptide repertoire from human respiratory syncytial virus is focused on major structural proteins with the exception of the viral polymerase. <i>Journal of Proteomics</i> , 2020, 221, 103759.	1.2	2
6	Modulation of Natural HLA-B*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2). <i>Molecular and Cellular Proteomics</i> , 2020, 19, 994-1004.	2.5	15
7	Immunoproteomic analysis of a Chikungunya poxvirus-based vaccine reveals high HLA class II immunoprevalence. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007547.	1.3	4
8	Natural Spleen Cell Ligandome in Transporter Antigen Processing-Deficient Mice. <i>Journal of Proteome Research</i> , 2019, 18, 3512-3520.	1.8	7
9	The Conserved Non-Coding Sequence 2 (CNS2) Enhances CD69 Transcription through Cooperation between the Transcription Factors Oct1 and RUNX1. <i>Genes</i> , 2019, 10, 651.	1.0	4
10	Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet's Disease-associated HLA-B*51 Peptidome*[S]. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1491-1510.	2.5	17
11	Immunoproteomic Lessons for Human Respiratory Syncytial Virus Vaccine Design. <i>Journal of Clinical Medicine</i> , 2019, 8, 486.	1.0	2
12	Proteomics Analysis Reveals That Structural Proteins of the Virion Core and Involved in Gene Expression Are the Main Source for HLA Class II Ligands in Vaccinia Virus-Infected Cells. <i>Journal of Proteome Research</i> , 2019, 18, 900-911.	1.8	8
13	Substantial Influence of ERAP2 on the HLA-B*40:02 Peptidome: Implications for HLA-B*27-Negative Ankylosing Spondylitis. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 2298-2309.	2.5	6
14	Complex antigen presentation pathway for an HLA-A*0201-restricted epitope from Chikungunya 6K protein. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006036.	1.3	7
15	Structural and Nonstructural Viral Proteins Are Targets of T-Helper Immune Response against Human Respiratory Syncytial Virus. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 2141-2151.	2.5	10
16	The Viral Transcription Group Determines the HLA Class I Cellular Immune Response Against Human Respiratory Syncytial Virus*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 893-904.	2.5	13
17	A Common Minimal Motif for the Ligands of HLA-B*27 Class I Molecules. <i>PLoS ONE</i> , 2014, 9, e106772.	1.1	1
18	Natural HLA-B*2705 Protein Ligands with Glutamine as Anchor Motif. <i>Journal of Biological Chemistry</i> , 2013, 288, 10882-10889.	1.6	21

#	ARTICLE	IF	CITATIONS
19	Vaccination and the TAP-independent antigen processing pathways. <i>Expert Review of Vaccines</i> , 2013, 12, 1077-1083.	2.0	6
20	Diversity of Natural Self-Derived Ligands Presented by Different HLA Class I Molecules in Transporter Antigen Processing-Deficient Cells. <i>PLoS ONE</i> , 2013, 8, e59118.	1.1	8
21	Concerted In Vitro Trimming of Viral HLA-B27-Restricted Ligands by Human ERAP1 and ERAP2 Aminopeptidases. <i>PLoS ONE</i> , 2013, 8, e79596.	1.1	25
22	Reply to Clinical and Immunological Remarks about TAP Deficiency. <i>Journal of Biological Chemistry</i> , 2012, 287, 27048.	1.6	0
23	A Viral, Transporter Associated with Antigen Processing (TAP)-independent, High Affinity Ligand with Alternative Interactions Endogenously Presented by the Nonclassical Human Leukocyte Antigen E Class I Molecule. <i>Journal of Biological Chemistry</i> , 2012, 287, 34895-34903.	1.6	13
24	Multiple Viral Ligands Naturally Presented by Different Class I Molecules in Transporter Antigen Processing-Deficient Vaccinia Virus-Infected Cells. <i>Journal of Virology</i> , 2012, 86, 527-541.	1.5	18
25	Role of Metalloproteases in Vaccinia Virus Epitope Processing for Transporter Associated with Antigen Processing (TAP)-independent Human Leukocyte Antigen (HLA)-B7 Class I Antigen Presentation*. <i>Journal of Biological Chemistry</i> , 2012, 287, 9990-10000.	1.6	14
26	CD69 Does Not Affect the Extent of T Cell Priming. <i>PLoS ONE</i> , 2012, 7, e48593.	1.1	19
27	TAP-independent human histocompatibility complex-Cw1 antigen processing of an HIV envelope protein conserved peptide. <i>Aids</i> , 2011, 25, 265-269.	1.0	5
28	Allele-dependent Processing Pathways Generate the Endogenous Human Leukocyte Antigen (HLA) Class I Peptide Repertoire in Transporters Associated with Antigen Processing (TAP)-deficient Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 38054-38059.	1.6	13
29	Unusual viral ligand with alternative interactions is presented by HLA-B*07:02 in human respiratory syncytial virus-infected cells. <i>Immunology and Cell Biology</i> , 2011, 89, 558-565.	1.0	7
30	Multiple, Non-conserved, Internal Viral Ligands Naturally Presented by HLA-B27 in Human Respiratory Syncytial Virus-infected Cells. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 1533-1539.	2.5	23
31	Cutting Edge: H-2Ld Class I Molecule Protects an HIV N-Extended Epitope from In Vitro Trimming by Endoplasmic Reticulum Aminopeptidase Associated with Antigen Processing. <i>Journal of Immunology</i> , 2010, 184, 3351-3355.	0.4	19
32	Non-ionic and cationic micelle nanostructures as drug solubilization vehicles: spectrofluorimetric and electrochemical studies. <i>Colloid and Polymer Science</i> , 2007, 285, 1321-1329.	1.0	7